TY - JOUR
T1 - ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis
AU - Zipeto, Maria Anna
AU - Court, Angela C.
AU - Sadarangani, Anil
AU - Delos Santos, Nathaniel P.
AU - Balaian, Larisa
AU - Chun, Hye Jung
AU - Pineda, Gabriel
AU - Morris, Sheldon R.
AU - Mason, Cayla N.
AU - Geron, Ifat
AU - Barrett, Christian
AU - Goff, Daniel J.
AU - Wall, Russell
AU - Pellecchia, Maurizio
AU - Minden, Mark
AU - Frazer, Kelly A.
AU - Marra, Marco A.
AU - Crews, Leslie A.
AU - Jiang, Qingfei
AU - Jamieson, Catriona H.M.
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/8/4
Y1 - 2016/8/4
N2 - Post-transcriptional adenosine-to-inosine RNA editing mediated by adenosine deaminase acting on RNA1 (ADAR1) promotes cancer progression and therapeutic resistance. However, ADAR1 editase-dependent mechanisms governing leukemia stem cell (LSC) generation have not been elucidated. In blast crisis chronic myeloid leukemia (BC CML), we show that increased JAK2 signaling and BCR-ABL1 amplification activate ADAR1. In a humanized BC CML mouse model, combined JAK2 and BCR-ABL1 inhibition prevents LSC self-renewal commensurate with ADAR1 downregulation. Lentiviral ADAR1 wild-type, but not an editing-defective ADAR1E912A mutant, induces self-renewal gene expression and impairs biogenesis of stem cell regulatory let-7 microRNAs. Combined RNA sequencing, qRT-PCR, CLIP-ADAR1, and pri-let-7 mutagenesis data suggest that ADAR1 promotes LSC generation via let-7 pri-microRNA editing and LIN28B upregulation. A small-molecule tool compound antagonizes ADAR1’s effect on LSC self-renewal in stromal co-cultures and restores let-7 biogenesis. Thus, ADAR1 activation represents a unique therapeutic vulnerability in LSCs with active JAK2 signaling.
AB - Post-transcriptional adenosine-to-inosine RNA editing mediated by adenosine deaminase acting on RNA1 (ADAR1) promotes cancer progression and therapeutic resistance. However, ADAR1 editase-dependent mechanisms governing leukemia stem cell (LSC) generation have not been elucidated. In blast crisis chronic myeloid leukemia (BC CML), we show that increased JAK2 signaling and BCR-ABL1 amplification activate ADAR1. In a humanized BC CML mouse model, combined JAK2 and BCR-ABL1 inhibition prevents LSC self-renewal commensurate with ADAR1 downregulation. Lentiviral ADAR1 wild-type, but not an editing-defective ADAR1E912A mutant, induces self-renewal gene expression and impairs biogenesis of stem cell regulatory let-7 microRNAs. Combined RNA sequencing, qRT-PCR, CLIP-ADAR1, and pri-let-7 mutagenesis data suggest that ADAR1 promotes LSC generation via let-7 pri-microRNA editing and LIN28B upregulation. A small-molecule tool compound antagonizes ADAR1’s effect on LSC self-renewal in stromal co-cultures and restores let-7 biogenesis. Thus, ADAR1 activation represents a unique therapeutic vulnerability in LSCs with active JAK2 signaling.
UR - http://www.scopus.com/inward/record.url?scp=84990898357&partnerID=8YFLogxK
U2 - 10.1016/j.stem.2016.05.004
DO - 10.1016/j.stem.2016.05.004
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 27292188
AN - SCOPUS:84990898357
SN - 1934-5909
VL - 19
SP - 177
EP - 191
JO - Cell Stem Cell
JF - Cell Stem Cell
IS - 2
ER -